Gy

Vejle Hospital becomes first center in the world to use RayStation for an online adaptive treatment with augmented CBCT

Retrieved on: 
Monday, November 20, 2023
Online, Gy, Acquisition, Teaching hospital, RaySearch Laboratories, CBCT, Workflow, Cancer, VMAT, Health, Pharmaceutical industry, Medical imaging

The improved workflow is enabled by the adaptive replanning capabilities of RayStation®* and significantly saves time for the patient.

Key Points: 
  • The improved workflow is enabled by the adaptive replanning capabilities of RayStation®* and significantly saves time for the patient.
  • Thanks to the synthetic CT algorithm and fast adaptive replanning capabilities in RayStation, the CBCT of the first treatment fraction can be used for creating an adapted plan during the treatment session.
  • In the current example, the online adaptation was motivated by differences in positioning at image acquisition and at treatment.
  • RayStation has very advanced tools available for taking online adaptive into clinical routine and the work done by Vejle is showcasing what groundbreakning possibilities our users have to further advance cancer treatments."

Plus Therapeutics Completes Enrollment of Cohort 1 ReSPECT-LM Phase 1/2a Trial

Retrieved on: 
Thursday, June 16, 2022
Gy, MFD, Spinal cord, Lymphatic system, Cancer, Review, FDA, NDA, Safety, Ayub Ommaya, Perception, MTD, Company, Brain, U.S. Securities and Exchange Commission, Research, Fast Track, New Drug Application, PSTV, Disease, DNA, Liposome, Physician, Nasdaq, Radiation, SVP, Incidence, LM, Patient, White Light Rock & Roll Review, Toxic leukoencephalopathy, Communication, Neoplasm, Toxicity, Membrane, Accelerated approval (FDA), Therapy, Priority review, GLOBE, Meninges, Index (publishing), Pharmaceutical industry, Medical imaging

AUSTIN, Texas, June 16, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced the completion of enrollment in the first cohort of the ReSPECT-LM Phase 1/2a dose escalation clinical trial of Rhenium-186 NanoLiposome (186RNL) for the treatment of leptomeningeal metastases (LM).

Key Points: 
  • We are pleased with initial response to the ReSPECT-LM trial by patients and physicians and the very early promising drug performance, said Norman LaFrance, M.D., Chief Medical Officer and SVP of Plus Therapeutics.
  • We intend to provide enrollment and complete clinical updates in the third quarter of 2022.
  • The ReSPECT-LM trial ( NCT05034497 ) is a multicenter, sequential cohort, open-label, single dose, dose escalation Phase 1/2a study using a modified Fibonacci 3+3 study design.
  • The primary endpoints of the study are the incidence and severity of adverse events/serious adverse events and dose limiting toxicities.

Plus Therapeutics Announces First Patient Dosed in Phase 1/2a Dose Escalation Trial of 186RNL Radiotherapeutic for Leptomeningeal Metastases

Retrieved on: 
Tuesday, March 22, 2022
Spinal cord, Company, Cancer, Therapy, Life, Meninges, Glioblastoma, Fast Track, DNA, LM, Principal investigator, Toxicity, White Light Rock & Roll Review, MFD, Central nervous system, MTD, CNS, Research, Gastrointestinal cancer, Liposome, Perception, Food and Drug Administration, Neoplasm, Incidence, Ayub Ommaya, Food, Neuro-Oncology (journal), Membrane, Communication, University of Texas Southwestern Medical Center, Lymphatic system, Index (publishing), SVP, New Drug Application, Accelerated approval (FDA), Safety, Review, Assistant, Priority review, Nasdaq, U.S. Securities and Exchange Commission, Brain, GLOBE, Melanoma, NDA, Toxic leukoencephalopathy, Gy, PSTV, FDA, Breast cancer, Lung cancer, University, Patient, Disease, Prognosis, Radiation, Pharmaceutical industry, Medical imaging

AUSTIN, Texas, March 22, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that the first patient has been dosed in the ReSPECT-LM Phase 1/2a dose escalation clinical trial of Rhenium-186 NanoLiposome (186RNL) for the treatment of patients with leptomeningeal metastases (LM).

Key Points: 
  • The investigational drug, 186RNL, is a proprietary nanoscale compound with a unique chelated radioisotope that is administered locally as a single dose via a conventional Ommaya reservoir.
  • Initiating treatment in LM patients with 186RNL marks an important milestone for Plus Therapeutics and potentially for the LM patient population.
  • The ReSPECT-LM trial ( NCT05034497 ) is a multicenter, sequential cohort, open-label, single dose, dose escalation Phase 1/2a study using a modified Fibonacci 3+3 study design.
  • The primary endpoints of the study are the incidence and severity of adverse events/serious adverse events and dose limiting toxicities.

Plus Therapeutics Announces Positive Interim Data from ReSPECT™-GBM Phase 1 Clinical Trial at the 2021 Society for Neuro-Oncology Annual Meeting

Retrieved on: 
Thursday, November 18, 2021
Liposome, Patient, Perception, University of Texas Southwestern Medical Center, Safety, University, Cancer, Conference, CMC, Toxic leukoencephalopathy, Plus, Death, Company, GBM, University of Texas System, UT, Feasibility, University of Texas Health Science Center at San Antonio, Nasdaq, Survival, Gy, Neurosurgery, Neoplasm, Research, Education, Adult, GLOBE, Neurology, Orphan drug, Fast Track, Q&A, PSTV, OS, FDA, Radiation, Unit, U.S. Securities and Exchange Commission, Poster, Observation, AES, Therapy, Convection, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, CED, Food, Investor relations, Pharmaceutical industry, Medical imaging

AUSTIN, Texas, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a U.S. clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today released positive interim data on its lead investigational drug, Rhenium-186 NanoLiposome (186RNL), from the first-in-man Phase 1 ReSPECT™-GBM clinical trial in patients with recurrent glioblastoma (GBM) at the 2021 Society for Neuro-Oncology Annual Meeting and Education Day being held in Boston, Massachusetts.

Key Points: 
  • A positive correlation was observed between overall survival and higher absorbed radiation doses (greater than 100 Gy).
  • No dose limiting toxicities or adverse events (AEs) with the outcome of death, or discontinuations due to AEs have been observed.
  • For a more detailed discussion of the ReSPECT-GBM trial data, please join the Plus Therapeutics hosted webinar on Thursday, November 18, 2021, 4:00 to 5:00 p.m.
  • A live webinar with accompanying slides will be available in the Events page of the Investor Relations section of the Plus Therapeutics website.

Plus Therapeutics Announces FDA Clearance of Investigational New Drug Application for 186RNL for the Treatment of Leptomeningeal Metastases

Retrieved on: 
Tuesday, October 19, 2021
Membrane, Gy, Toxicity, IND, Regulation, University, Perception, Neurosurgery, Cancer, U.S. Securities and Exchange Commission, Lung cancer, Metastasis, Incidence, Spinal cord, Melanoma, Breast cancer, Disease, Central nervous system, Lincoln Park, Research, Glioblastoma, Intellectual property, Neoplasm, University of Texas at Austin, PSTV, FDA, Nasdaq, Meninges, Therapy, Brain, GLOBE, Neurology, Survival, LM, Patient, Radiation, Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Liposome, Marketing, Safety, C6, Company, Pharmaceutical industry

AUSTIN, Texas, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a U.S. clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) for Rhenium-186 NanoLiposome (186RNL) for the treatment of leptomeningeal metastases (LM). The Company expects to initiate patient accrual in a Phase 1 dose escalation trial of 186RNL (ReSPECT-LM) in the fourth quarter of 2021.

Key Points: 
  • The Company expects to initiate patient accrual in a Phase 1 dose escalation trial of 186RNL (ReSPECT-LM) in the fourth quarter of 2021.
  • The ReSPECT-LM trial is a multicenter, sequential cohort, open-label, single dose, dose escalation Phase 1 study.
  • The primary endpoint of the study is the incidence and severity of adverse events/serious adverse events and dose limiting toxicities.
  • Leptomeningeal metastasis is a neurologically devastating and fatal complication of cancer, said Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics.

SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Parsley Energy, Inc. Merger

Retrieved on: 
Tuesday, October 20, 2020
Common law, Equity, Fiduciary, New York Stock Exchange, Parsley, Gy, Ene, New York City

announces that it is investigating Parsley Energy, Inc. (Parsley) (NYSE: PE ) regarding possible breaches of fiduciary duties and other violations of law related to Parsleys agreement to be acquired by Pioneer Natural Resources Company (Pioneer) (NYSE: PXD ).

Key Points: 
  • announces that it is investigating Parsley Energy, Inc. (Parsley) (NYSE: PE ) regarding possible breaches of fiduciary duties and other violations of law related to Parsleys agreement to be acquired by Pioneer Natural Resources Company (Pioneer) (NYSE: PXD ).
  • Under the terms of the agreement, Parsleys shareholders will receive 0.1252 of a share of Pioneer per share.
  • To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-parsley-ene r gy-inc .
  • You may also contact Seth D. Rigrodsky or Gina M. Serra cost and obligation free at (888) 969-4242 or [email protected] .